Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.
advertisement
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
Share
Save
Restart
Resume
Transcript
RENEU (A Study to Evaluate the Safety, Effectiveness, and Tolerability of Gomekli in Children Aged ≥2 Years and Adults with an Inoperable NF1-PN; NCT03962543)
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Christopher Moertel, MD, Medical Director of the Pediatric Neuro-Oncology and Neurofibromatosis Programs at the University of Minnesota provides an overview of the ReNeu clinical trial which evaluated the safety, effectiveness, and tolerability of Gomekli in children aged ≥2 years and adults.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?